Literature DB >> 18502541

Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.

Richard S Agnes1, Jinfa Ying, Katalin E Kövér, Yeon Sun Lee, Peg Davis, Shou-wu Ma, Hamid Badghisi, Frank Porreca, Josephine Lai, Victor J Hruby.   

Abstract

Prolonged opioid exposure increases the expression of cholecystokinin (CCK) and its receptors in the central nervous system (CNS), where CCK may attenuate the antinociceptive effects of opioids. The complex interactions between opioid and CCK may play a role in the development of opioid tolerance. We designed and synthesized cyclic disulfide peptides and determined their agonist properties at opioid receptors and antagonist properties at CCK receptors. Compound 1 (Tyr-c[d-Cys-Gly-Trp-Cys]-Asp-Phe-NH(2)) showed potent binding and agonist activities at delta and mu opioid receptors but weak binding to CCK receptors. The NMR structure of the lead compound displayed similar conformational features of opioid and CCK ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502541      PMCID: PMC2601673          DOI: 10.1016/j.peptides.2008.03.022

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  38 in total

Review 1.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors.

Authors:  F Noble; S A Wank; J N Crawley; J Bradwejn; K B Seroogy; M Hamon; B P Roques
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

Review 2.  The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance.

Authors:  Z Wiesenfeld-Hallin; X J Xu
Journal:  Regul Pept       Date:  1996-08-27

3.  Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.

Authors:  Richard S Agnes; Yeon Sun Lee; Peg Davis; Shou-Wu Ma; Hamid Badghisi; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

4.  Conformational studies of RS-66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity.

Authors:  M Pellegrini; A Bisello; M Rosenblatt; M Chorev; D F Mierke
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

Review 5.  CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.

Authors:  F Noble; B P Roques
Journal:  Prog Neurobiol       Date:  1999-07       Impact factor: 11.685

6.  Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy.

Authors:  M Pellegrini; D F Mierke
Journal:  Biochemistry       Date:  1999-11-09       Impact factor: 3.162

7.  Cyclic enkephalin analogs that are hybrids of DPDPE-related peptides and metenkephalin-Arg-Gly-Leu: prohormone analogs that retain good potency and selectivity for delta opioid receptors.

Authors:  H Bartosz-Bechowski; P Davis; J Slaninova; E Malatynska; D Stropova; F Porreca; H I Yamamura; V J Hruby
Journal:  J Pept Res       Date:  1999-03

8.  Cyclic enkephalin analogues with exceptional potency and selectivity for delta-opioid receptors.

Authors:  V J Hruby; H Bartosz-Bechowski; P Davis; J Slaninova; T Zalewska; D Stropova; F Porreca; H I Yamamura
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

Review 9.  Challenges in the development of novel treatment strategies for neuropathic pain.

Authors:  Michael H Ossipov; Frank Porreca
Journal:  NeuroRx       Date:  2005-10

10.  Conformationally constrained cyclic enkephalin analogs with pronounced delta opioid receptor agonist selectivity.

Authors:  H I Mosberg; R Hurst; V J Hruby; J J Galligan; T F Burks; K Gee; H I Yamamura
Journal:  Life Sci       Date:  1983-05-30       Impact factor: 5.037

View more
  8 in total

1.  Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Authors:  Junesun Kim; Youngkyung Kim; Suk-Chan Hahm; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

Review 2.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

3.  Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.

Authors:  Yeon Sun Lee; Steve Fernandes; Vinod Kulkarani; Alexander Mayorov; Peg Davis; Shou-wu Ma; Kathy Brown; Robert J Gillies; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2010-05-24       Impact factor: 2.823

4.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.

Authors:  Katherine E Hanlon; Dave S Herman; Richard S Agnes; Tally M Largent-Milnes; Isuru R Kumarasinghe; Sho W Ma; Wenhong Guo; Yeon-Sun Lee; Michael H Ossipov; Victor J Hruby; Josephine Lai; Frank Porreca; Todd W Vanderah
Journal:  Brain Res       Date:  2011-04-20       Impact factor: 3.252

Review 5.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

Review 6.  Novel Pharmacological Nonopioid Therapies in Chronic Pain.

Authors:  Alan David Kaye; Elyse M Cornett; Brendon Hart; Shilpadevi Patil; Andrew Pham; Matthew Spalitta; Kenneth F Mancuso
Journal:  Curr Pain Headache Rep       Date:  2018-04-03

Review 7.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 8.  Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.

Authors:  Keith M Olson; Wei Lei; Attila Keresztes; Justin LaVigne; John M Streicher
Journal:  Yale J Biol Med       Date:  2017-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.